Kushner, Pamela
Khunti, Kamlesh
Cebrián, Ana
Deed, Gary
Article History
Received: 17 May 2024
Accepted: 25 July 2024
First Online: 20 August 2024
Declarations
:
: Ana Cebrián has received grants from Merck Sharp & Dohme and speaker honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Merck Sharp & Dohme, Mundipharma, Novartis Pharmaceuticals, Novo Nordisk, and Sanofi. Gary Deed reports advisory board fees from AstraZeneca and Boehringer Ingelheim, as well as non-financial involvement in the START Trial (The George Institute) of SGLT2 inhibitors as first-line therapy to improve renal outcomes in T2D. He is a consultant to Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi, and Sequiris. Kamlesh Khunti has received consultancy fees from Amgen, AstraZeneca, Bristol Myers-Squibb, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Sanofi, Servier, Pfizer, Roche, Daiichi-Sankyo, Embecta, and Nestlé Health Science; research support from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Merck, Novo Nordisk, Roche, Sanofi, Servier, Oramed Pharmaceuticals, Daiichi-Sankyo, and Applied Therapeutics; and speaker’s bureau fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Merck, Novo Nordisk, Sanofi, Servier, and Roche. Pamela Kushner has received speaker’s bureau and advisory board fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, and Novo Nordisk A/S; speaker’s fees from Bayer AG and Boehringer Ingelheim; and honoraria from AstraZeneca and Eli Lilly and Company.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.